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Background: Extracellular adenosine
5*-triphosphate (ATP) is involved in
the regulation of a variety of biologic
processes, including neurotransmission,
muscle contraction, and liver glucose
metabolism, via purinergic receptors.
In nonrandomized studies involving
patients with different tumor types in-
cluding non-small-cell lung cancer
(NSCLC), ATP infusion appeared to
inhibit loss of weight and deterioration
of quality of life (QOL) and perfor-
mance status. We conducted a random-
ized clinical trial to evaluate the effects
of ATP in patients with advanced
NSCLC (stage IIIB or IV). Methods:
Fifty-eight patients were randomly as-
signed to receive either 10 intravenous
30-hour ATP infusions, with the infu-
sions given at 2- to 4-week intervals, or
no ATP. Outcome parameters were as-
sessed every 4 weeks until 28 weeks. Be-
tween-group differences were tested for
statistical significance by use of re-
peated-measures analysis, and reported
P values are two-sided. Results:
Twenty-eight patients were allocated to
receive ATP treatment and 30 received
no ATP. Mean weight changes per
4-week period were −1.0 kg (95% con-
fidence interval [CI] = −1.5 to −0.5) in
the control group and 0.2 kg (95% CI =
−0.2 to +0.6) in the ATP group (P =
.002). Serum albumin concentration
declined by −1.2 g/L (95% CI= −2.0 to
−0.4) per 4 weeks in the control group
but remained stable (0.0 g/L; 95% CI =
−0.3 to +0.3) in the ATP group (P =
.006). Elbow flexor muscle strength de-
clined by −5.5% (95% CI = −9.6% to
−1.4%) per 4 weeks in the control
group but remained stable (0.0%; 95%
CI= −1.4% to +1.4%) in the ATP group
(P = .01). A similar pattern was ob-
served for knee extensor muscles (P =
.02). The effects of ATP on body
weight, muscle strength, and albumin
concentration were especially marked
in cachectic patients (P = .0002, P =
.0001, and P = .0001, respectively, for
ATP versus no ATP). QOL score
changes per 4-week period in the ATP
group showed overall less deterioration
than in the control group—physical
scores (−0.2% versus −2.4%; P =
.0002); functional scores (+0.4% versus
−5.5%; P = .02); psychologic scores
(−0.7% versus −2.4%; P = .11); overall
QOL score (+0.1% versus −3.5%; P =
.0001). Conclusions: This randomized
trial demonstrates that ATP has ben-
eficial effects on weight, muscle
strength, and QOL in patients with ad-
vanced NSCLC. [J Natl Cancer Inst
2000;92:321–8]
Cachexia contributes significantly to
the high morbidity and mortality in pa-
tients with advanced non-small-cell lung
cancer (NSCLC) (1,2). Maintenance of
weight and of quality of life (QOL) is,
therefore, an important issue in the pallia-
tive treatment of patients with advanced
NSCLC. Dietary counseling (3,4) and the
use of enteral supplements (4) have failed
to reverse weight loss. Drugs, including
corticosteroids (5), cyproheptadine (6),
hydrazine sulfate (7), pentoxifylline (8),
and anabolic steroids (9), were also
shown to be ineffective. Prostagens re-
duced weight loss or increased weight,
mainly as fat gain (10,11). Although QOL
was not influenced by prostagens in all
studies (11–13), in some studies (14,15) it
was also improved.
Adenosine 58-triphosphate (ATP) is a
naturally occurring nucleoside triphos-
phate that plays a central role as an energy
source in every cell of the human body. In
addition, extracellular ATP is involved in
the regulation of a variety of biologic pro-
cesses, including neurotransmission,
muscle contraction, and liver glucose me-
tabolism, by stimulation of purinergic re-
ceptors (16). Intravenous ATP may offer
a novel palliative approach in the treat-
ment of NSCLC. ATP given by daily in-
traperitoneal injection for 10 days to mice
with colon tumors significantly inhibited
weight loss (17). Recently, in the United
States, a small open phase II trial in 15
patients with NSCLC (stage IIIB or IV)
(18) demonstrated maintenance of weight,
QOL, and performance status after treat-
ment with two to four intravenous infu-
sions of ATP (50–65 mg/kg per minute)
for 96 hours given at 4-week intervals.
These results supported earlier findings
from a phase I study in 14 cancer patients
(19). On the basis of these promising pre-
liminary reports, we conducted a random-
ized clinical trial to evaluate the effect of
ATP infusion on body weight, muscle
strength, and QOL in patients with ad-
vanced NSCLC (stage IIIB or IV).
PATIENTS AND METHODS
Patient Eligibility, Randomization,
and Study Design
During the period from January 1996 through No-
vember 1998, 58 patients were entered in the study.
Eligible subjects were patients with histologically or
cytologically proven NSCLC of stage IIIB or IV
(20) and a Karnofsky index of 60% or higher (21).
Exclusion criteria were as follows: eligibility for cu-
rative treatment, liver failure, renal failure (defined
as patients needing limitation of fluid intake), respi-
ratory failure (defined as O2 dependence), heart fail-
ure, angina pectoris, cognitive dysfunction, or psy-
chiatric illness. The study was approved by the
Medical Ethical Committee of the Erasmus Univer-
sity Medical Center Rotterdam. Written informed
consent was obtained from all patients prior to the
study.
A randomization list was prepared by the Medical
Oncology Trial Office of the Erasmus University
Medical Center Rotterdam with the use of block
randomization in permutation blocks of four. After
baseline measurements, patients were stratified ac-
cording to tumor stage (IIIB versus IV), previous
treatment (chemotherapy versus no chemotherapy),
and performance status (Karnofsky index, >70 ver-
sus ł70); they were then randomly assigned to re-
ceive either supportive care and ATP (ATP group)
or supportive care alone (control group). Supportive
care, provided by the patients’ attending physicians,
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included analgesics, antibiotics, anticough medica-
tion, antiemetics, bisphosphonates, corticosteroids,
and palliative radiotherapy for local control of the
primary tumor or metastases.
Patients in the ATP-treatment arm were admitted
to the Clinical Research Unit of the University Hos-
pital of the Erasmus University Medical Center Rot-
terdam to receive a maximum of 10 ATP courses. To
keep hospitalization at a minimum for ethical rea-
sons, we chose not to use the schedule used by
Haskell et al. (18,19) with ATP infusions for 96
hours once every 4 weeks; instead, we gave 30-hour
infusions at shorter intervals, i.e., the first seven
ATP courses at 2-week intervals, followed by three
ATP courses at 4-week intervals. ATP infusions (6.1
mg/mL in 0.9% NaCl) were started beginning at a
dose of 20 mg/kg per minute and were increased by
increments of 10 mg/kg per minute every 30 minutes
until a maximum dose of 75 mg/kg per minute was
reached or until the maximally tolerated dose, if this
was lower, had been reached. Thereafter, ATP was
infused at a continuous rate. If any side effects oc-
curred, the dose was reduced to the last lower dose
or further reduced until side effects disappeared.
Follow-up was continued until week 28, i.e., 4
weeks after the last ATP course that was given at 24
weeks. Patients in the control arm were followed up
at the outpatient department of the Erasmus Univer-
sity Medical Center Rotterdam for 28 weeks. In both
groups, anthropometry, blood serum albumin levels,
muscle strength, and QOL were assessed before
treatment randomization and after randomization at
4-, 8-, 12-, 16-, 20-, 24-, and 28-week periods.
Anthropometry and Muscle Strength
Body height was determined to the nearest centi-
meter. Body weight was measured with an elec-
tronic scale (Seca Ltd., Birmingham, U.K.) to the
nearest 0.1 kg.
Strengths of two muscle groups (i.e., elbow flexor
muscles and knee extensor muscles) were assessed
by use of a hand-held Microfet2R dynamometer
(Biometrics Europe, Amersfoort, The Netherlands).
This technique has been validated in several groups
of patients, mostly in those patients who were lim-
ited in muscle strength (22,23). The patient while
sitting exerted a maximal force with the 90° flexed
right elbow, while the examiner pushed with the
dynamometer against the patient’s thumb pad until
the muscle strength was overcome (break test).
Similarly, the patient exerted a maximal force with
the 90° flexed right knee, while the examiner pushed
with the dynamometer against the patient’s ankle
until the muscle strength was overcome. The
strength of both muscle groups was measured three
times at an interval of approximately 10 seconds.
Muscle strength was expressed in Newtonmeter
(Nm) units and was calculated by dividing the mea-
sured mean strength (dynamometer reading) by the
distance from the dynamometer position point to the
humeral epicondylus medialis (elbow) and the fe-
mural epicondylus medialis (knee). The same ob-
server (H. J. Agteresch) carried out all measure-
ments.
Quality of Life
QOL was assessed with the use of The Rotterdam
Symptom Checklist (RSCL), a 39-item self-report
questionnaire (24). The reliability and validity of the
RSCL in cancer patients have been confirmed in
both cross-sectional (25) and longitudinal (26,27)
studies in patients with a wide range of cancers. This
questionnaire, which assesses symptoms during the
preceding week, was filled out by the patients. The
RSCL measures scores on four domains: 1) a physi-
cal score (23 items), 2) a psychologic score (seven
items), 3) a functional score (eight items), and 4) an
overall score (one item). Each item is rated on a
4-point scale. Results per item were transformed
into standardized scores, ranging from 0 to 100 with
the use of the following formula: 100 – [100 × (item
scale score – minimum item score)/(maximum score
– minimum score)]. A lower score represents a
greater level of distress (24).
Statistical Analysis
Differences over time between body weight, se-
rum albumin levels, muscle strength, and QOL
scores in the two groups were analyzed according to
the “intention-to-treat” principle by repeated-
measures analysis of covariance with the use of the
linear regression model. To account for the within-
patient correlation in the measurements of the de-
pendent variable and, simultaneously, for possible
non-normality of the dependent variable, the Gener-
alized Estimating Equations (28) approach was fol-
lowed. These analyses were performed with the SAS
procedure Proc Mixed (version 6.12-Windows; SAS
Inc., Cary, NC), with the use of the independence
working correlation structure. Independent variables
in the model were the treatment indicator variable,
baseline measurement, measurement time, and inter-
action between time and treatment. This model as-
sumes a linear relation between measurement and
time in both treatment groups, which was checked
by adding quadratic time terms. Statistical signifi-
cance of the treatment effect was assessed by testing
the null hypothesis that the coefficients of the treat-
ment indicator and its interaction with time are si-
multaneously equal to zero. Survival was compared
between groups by means of the log-rank test with
the use of SPSS (version 6.1.3-Windows; SPSS Inc.,
Chicago, IL). Two-sided P values less than .05 were
considered statistically significant.
RESULTS
Data on Patients
Twenty-eight patients were allocated
to ATP treatment, and 30 were assigned
to no ATP treatment. The trial design is
summarized in Fig. 1. Age, tumor stage,
performance status, previous treatment,
and outcome parameters were similar at
baseline between the ATP and control
arms. Assessable patients in the ATP
group weighed more and had lost more
weight than patients in the control group.
In both groups, the majority were male
(Table 1). However, when the statistical
analyses for all outcome parameters were
adjusted for age, sex, body weight, weight
loss, and histologic type, this did not alter
the results in both groups.
Twenty-eight patients in the ATP
group received a total of 176 ATP
courses. Eleven patients received one to
three ATP courses, five received four to
six courses, and 12 received seven to 10
courses. Fifty-two infusions of ATP were
given as low-dose infusions of 25–40 mg/
kg per minute, 47 as middle-dose infu-
sions of 45–60 mg/kg per minute, and 77
as high-dose infusions of 65–75 mg/kg
per minute. Sixty-seven percent of the
ATP courses were without side effects
(36% and 73% of first and subsequent
courses, respectively). Side effects were
monitored according to the Common
Toxicity Criteria (National Cancer Insti-
tute) graded on a 4-point scale according
to seriousness. During ATP infusions, the
most frequently reported side effects (ex-
pressed as percent of total number of in-
fusions [n 4 176] resulting in the side
effects) were of type 1 (chest discomfort,
15%; urge to take a deep breath, 10%;
flushing, 5%; nausea, 5%; lightheaded-
ness, 3%; headache, 2%; sweating, 2%;
mood alteration–anxiety, 2%; and palpi-
tations, 1%). Few side effects were of
type 2 (injection side reaction, 3%), and
none were of type 3. Although mild, one
side effect was of type 4 (dyspnea, 3%).
In patients with chest discomfort during
ATP infusion, electrocardiography (ECG)
was performed. In no case were ECG
changes suggestive of myocardial isch-
emia detected. The side effects always re-
solved within minutes of lowering the
ATP dose.
Body Weight
In control patients, the mean weight
loss over the 28-week study period (ex-
pressed as change per 4 weeks) was −1.0
kg (95% CI 4 −1.5 to −0.5) per 4 weeks,
whereas ATP-treated patients experi-
enced no weight loss (0.2 kg; 95% CI 4
−0.2 to +0.6; P for between-group differ-
ence 4 .002; Fig. 2, A). For further
analysis, the participants were stratified
according to the presence of cachexia
prior to the study (ø5% versus <5%
weight loss in relation to weight before
the illness; 16 patients in the ATP group
and 13 patients in the control group ver-
sus 9 patients in the ATP group and 12
patients in the control group). In cachectic
patients, progressive weight loss of −1.6
kg (95% CI 4 −2.1 to −1.1) per 4 weeks
was observed in the control group, while
no additional weight loss occurred in the
ATP group (+0.3 kg; 95% CI 4 −0.5 to
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+1.1; P for between-group difference 4
.0002). In noncachectic patients, statisti-
cal significance between the study groups
was not reached (P 4 .22).
Serum Albumin Levels
Serum albumin concentration (g/L) de-
clined by −1.2 (95% CI 4 −2.0 to −0.4)
per 4 weeks in the control group, whereas
no change was detected in the ATP group
(0.0 g/L; 95% CI 4 −0.3 to +0.3; P for
between-group difference 4 .006; Fig.
3). The effect of ATP on albumin was
highly significant in patients who were
already cachectic at the beginning of the
study (P 4 .0001) but not in noncachectic
patients (P 4 .37).
Muscle Strength
The strength of elbow flexor muscles
declined by −5.5% (95% CI4 −9.6% to
−1.4%) per 4 weeks in the control group,
whereas values remained stable in the
ATP group (0.0%; 95% CI 4 −1.4% to
+1.4%; P for between-group difference
4 .01; Fig. 2, B, top). A similar pattern
was observed for knee extensor muscles:
Muscle strength in control patients de-
creased by −4.5% (95% CI 4 −9.7% to
−0.7%) per 4 weeks, whereas muscle
strength in ATP-treated patients showed
no significant change with time (+1.4%;
95% CI 4 −0.2% to +3.1%; P 4 .02;
Fig. 2, B, bottom). The effect of ATP on
the strength of elbow flexor and knee ex-
tensor muscles was highly significant in
patients who were already cachectic at the
beginning of the study (both P 4 .0001)
but not in noncachectic patients (P 4 .38
and P 4 .44, respectively).
Quality of Life
During follow-up, patients in the con-
trol group showed an impairment in their
physical QOL score of −2.4% (95% CI 4
−4.1% to −0.6%) per 4 weeks, whereas
patients in the ATP group showed no
change (−0.2%; 95% CI 4 −1.1% to
+0.7%; P for between-group difference
4 .0002; Fig. 4, A). The functional score
deteriorated by −5.5% (95% CI 4 −9.6%
to −1.4%) per 4 weeks in patients in the
control group, whereas patients in the
ATP group showed no significant change
(+0.4%; 95% CI 4 −1.8% to +2.6%; P
4 .02; Fig. 4, B). The psychologic score
deteriorated by −2.4% (95% CI 4 −5.9%
to +1.1%) per 4 weeks in patients in the
control group but showed no significant
change in patients in the ATP group
(−0.7%; 95% CI 4 −2.0% to +0.6%; P
4 .11). With regard to the overall score
of QOL, patients in the control group
showed a deterioration in QOL by −3.5%
(95% CI 4 −6.5% to −0.5%) per 4
weeks, whereas patients in the ATP group
showed no change (+0.1%; 95% CI 4
−1.8% to +2.0%; P 4 .0001; Fig. 4, C).
The positive effects of ATP on QOL were
similar in both cachectic and noncachec-
tic patients.
Comparison of single items contribut-
ing to significant differences in physical
scores between the ATP and control
groups showed beneficial effects of ATP
on tiredness (P 4 .0001), lack of energy
(P 4 .001), appetite (P 4 .0004), short-
ness of breath (P 4 .001), sore muscles
(P 4 .0007), shivering (P 4 .006), con-
stipation (P 4 .003), and difficulties in
concentrating (P 4 .0005). Items contrib-
uting to the significant difference in func-
tional deterioration between the ATP and
the control groups included self-care (P
4 .009), doing light housework (P 4
.031), doing heavy housework (P 4
.002), climbing stairs (P 4 .016), and
walking outdoors (P 4 .011). Of the
Fig. 1. Flow diagram for the randomized
trial of adenosine 58-triphosphate (ATP) in
the treatment of advanced non-small-cell
lung cancer. Body weight was not assess-
able because of hospitalization of one pa-
tient in the ATP group and two patients
in the control group; muscle strength was
not assessable because of hospitalization of
two patients in the ATP group and three
patients in the control group, and two addi-
tional patients in the control group were not
assessable because of a technical defect in
the dynamometer before randomization.
QOL 4 quality of life.
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items contributing to the psychologic
scores, only the score for irritability (P 4
.047) was significantly different between
the two groups.
Concomitant Supportive Treatment
During the 28-week follow-up period,
none of the patients underwent surgery.
One patient in the control group was
treated with chemotherapy, which con-
sisted of five courses of a combination of
cisplatin and etoposide given at 3-week
intervals, followed by radiotherapy in-
volving all lesions. Palliative radiotherapy
was given to seven patients in the control
group and to six patients in the ATP
group. Thirteen patients in the control
group and nine patients in the ATP group
used corticosteroids to treat symptoms of
brain edema (four patients in the ATP
group and one patient in the control
group), dyspnea (four patients in the ATP
group and 12 patients in the control
group), and nausea (one patient in the
ATP group and no patients in the control
group).
Survival
Twenty-eight weeks after randomiza-
tion, the median survival time was 5.6
months (95% CI 4 1.1–10.1 months) for
patients in the ATP group and 4.7 months
(95% CI 4 2.5–6.8 months) for patients
in the control group (P for between-group
difference 4 .51).
DISCUSSION
Traditional outcome variables in clini-
cal oncology have been survival and tu-
mor response. Although evaluation of the
functional status, the QOL, and the body
weight of cancer patients is increasingly
perceived as a major aspect of cancer
treatment (27,29), the number of studies
investigating these parameters remains
limited.
The aim of our study was to investigate
the effect of ATP on body weight and
QOL in patients with advanced-stage
NSCLC as well as its effect on arm and
leg muscle strength as functional and pa-
tient-relevant parameters. Since the trial
was performed in patients with advanced
lung cancer, hand-held dynamometry was
chosen because this technique is noninva-
sive. Clearly, the ideal method for assess-
ing treatment effects regarding QOL
would have been a double-blind, placebo-
controlled study. However, blinding was
not feasible because of the complexity of
ATP administration. Some side effects are
relatively specific to ATP so that both pa-
tients and investigators would have easily
recognized that ATP was being given. In
addition, there were ethical reasons for
not giving 10 placebo infusions to pa-
tients with advanced lung cancer with a
short life expectancy (3–6 months). De-
spite these limitations, the remarkably
consistent positive effects of ATP on
QOL and on objective parameters, such as
body weight and serum albumin levels,
seem to underline the validity of our re-
sults.
During treatment and follow-up, a sig-
nificant difference in mean weight loss
was observed between patients in the
ATP group and those in the control group.
Patients in the control group lost approxi-
mately 1 kg per 4 weeks or 6.5 kg over a
6-month period, whereas patients in the
ATP group had an average stable weight
over the 6-month period. In cancer pa-
tients, loss of body weight is mainly due
to loss of fat and of skeletal muscle mass
(30). In our study, control patients lost
approximately one third of their muscle
strength in both arms and legs over a
6-month period, whereas ATP-treated pa-
tients lost no muscle strength. The signifi-
Table 1. Baseline patient characteristics of the randomly assigned and assessable patients in the
adenosine 58-triphosphate (ATP) trial
ATP* Control*
Randomly assigned
(n 4 28)
Assessable†
(n 4 26)‡
Randomly assigned
(n 4 30)
Assessable†
(n 4 27)‡
Sex
Male 20 (71%) 19 (73%) 18 (60%) 16 (59%)
Female 8 (29%) 7 (27%) 12 (40%) 11 (41%)
Age, y 64 ± 13 64 ± 13 61 ± 10 62 ± 11
Tumor histology
Adenocarcinoma 11 (39%) 11 (42%) 6 (20%) 6 (22%)
Squamous cell carcinoma 10 (36%) 10 (38%) 11 (37%) 10 (37%)
Undifferentiated large-cell
carcinoma
4 (14%) 4 (15%) 9 (30%) 7 (26%)
Unspecified 3 (11%) 1 (4%) 4 (13%) 4 (15%)
Chemotherapy as pretreatment
Yes 12 (43%) 11 (42%) 14 (47%) 13 (48%)
No 16 (57%) 15 (58%) 16 (53%) 14 (52%)
Stage§
IIIB 13 (46%) 11 (42%) 14 (47%) 13 (48%)
IV 15 (54%) 15 (58%) 16 (53%) 14 (52%)
Karnofsky score
ł70 12 (43%) 11 (42%) 14 (47%) 13 (48%)
>70 16 (57%) 15 (58%) 16 (53%) 14 (52%)
Prior weight loss, kg\ 5.8 ± 6.5 6.2 ± 6.8 4.9 ± 6.7 4.1 ± 6.8
Prior weight loss, %\ 6.7 ± 7.1 7.1 ± 7.3 6.8 ± 9.7 5.6 ± 9.6
Weight, kg 75.0 ± 16.4 75.1 ± 17.1 68.2 ± 12.3 69.2 ± 12.1
Body mass index, kg/m2 25.3 ± 5.5 25.5 ± 5.9 23.8 ± 4.0 24.3 ± 4.0
Albumin, g/L 40.7 ± 4.5 40.6 ± 4.6 40.0 ± 4.5 40.5 ± 4.2
Elbow flexor strength, Nm 533 ± 110 541 ± 114 512 ± 116 527 ± 121
Knee extensor strength, Nm 828 ± 177 839 ± 151 797 ± 219 838 ± 207
Physical QOL score¶ 78.5 ± 13.7 77.9 ± 13.9 77.2 ± 12.2 78.1 ± 12.3
Psychologic QOL score¶ 69.0 ± 23.0 68.8 ± 23.8 70.3 ± 20.2 71.4 ± 19.5
Functional QOL score¶ 80.1 ± 19.4 79.9 ± 19.6 77.7 ± 21.6 79.3 ± 22.2
Overall QOL score¶ 62.3 ± 21.5 60.7 ± 24.5 57.2 ± 18.4 59.3 ± 18.1
*Scores were expressed as mean ± standard deviation or number (%).
†At least one follow-up analysis was performed.
‡Characteristics for weight and muscle strength, n 4 25 and 24, respectively, in the ATP group, and n 4
25 and 22, respectively, in the control group.
§See (20).
\Weight loss in relation to weight before illness.
¶Quality-of-life (QOL) scores ranging from 0 to 100; a lower score represents a greater degree of
symptoms.
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cant difference between patients in the
ATP group and those in the control group
in concentration of the nutritional param-
eter albumin provides a biochemical con-
firmation of the beneficial effects of ATP
on the nutritional and functional status of
patients with advanced lung cancer. It is
noteworthy that the effect of ATP on
weight loss, muscle strength, and serum
albumin concentration was especially
marked in patients who were already ca-
chectic at the start of the study, whereas
no statistical significance was reached in
noncachectic patients.
Furthermore, a statistically significant
difference in overall scores on the QOL
instrument evolved between patients in
the ATP group and those in the control
group. In the control group, the deteriora-
tion expected in patients with progressive
cancer was seen, whereas this deteriora-
tion was not observed in the ATP group.
The QOL of the patients in the control
group deteriorated significantly both at
the physical (2% per 4 weeks) and func-
tional (5% per 4 weeks) levels, whereas
these domains remained practically un-
changed in patients in the ATP group. The
physical and functional scores were sig-
nificantly different between patients in
the ATP group and those in the control
group, whereas the psychologic scores
were not different. Furthermore, patients
in the ATP group showed a significantly
better general activity level, including do-
ing housework, climbing stairs, and walk-
ing outdoors, which supports the validity
of the beneficial effects of ATP on muscle
strength. Items contributing to the better
physical scores in patients in the ATP
group included lung cancer-related (e.g.,
shortness of breath) as well as general
symptoms. It is noteworthy that the items
include two of the most common cancer-
related symptoms: tiredness and lack of
energy (31). Scores for chest pain and
coughing did not significantly differ be-
tween the two groups (P 4 .05 and P 4
.21, respectively).
In both groups of patients, palliative
radiotherapy was given to approximately
the same number of patients, whereas
more patients in the control group than in
the ATP group used corticosteroids. None
of the patients used corticosteroids as ap-
petite-stimulating drugs or other appetite
stimulators, such as cyproheptadine and
megestrol acetate. One ATP-treated pa-
tient used marihuana tea for nausea; how-
ever, in a recent placebo-controlled study
in patients with acquired immunodefi-
Fig. 2. Changes in A) body weight and B)
elbow flexor (top) and knee extensor (bot-
tom) muscle strength. Graphs represent
mean values, and bars represent 95% con-
fidence intervals. Two-sided P values for
differences between patients in the adeno-
sine 58-triphosphate (ATP) group and
patients in the control group were deter-
mined with the use of repeated-measures
analysis.
Fig. 3. Changes in serum albumin concen-
tration (mean ± 95% confidence interval).
Two-sided P value for difference between
patients in the adenosine 58-triphosphate
(ATP) group and patients in the control
group was determined with the use of re-
peated-measures analysis.
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ciency disease syndrome (32), no signifi-
cant effect of dronabinol (the active in-
gredient of marihuana) on body weight
was shown. This finding indicates that
differences between the patients in the
ATP group and those in the control
groups were not due to confounding ef-
fects of concomitant supportive treatment.
ATP was administered as a constant
intravenous infusion without side effects
in the majority of courses; if side effects
occurred, they disappeared rapidly when
the infusion rate was lowered. The re-
ported side effects were mostly of type 1
and sometimes of type 2. Although during
the courses some patients showed dys-
pnea (type 4), this side effect was mild in
nature. Since, in addition, no side effects
were observed between the ATP infu-
sions, ATP treatment appears to be a non-
toxic therapy in patients with advanced
lung cancer.
The mechanisms contributing to the ef-
fects of ATP on body weight, muscle
strength, and QOL are not well under-
stood. It is unlikely that the beneficial ef-
fects of ATP on body weight and QOL
would be caused simply by appetite-
stimulating effects, since appetite stimu-
lators, such as cyproheptadine (6) and
corticosteroids (33), did not influence the
body weights of cancer patients. Rather,
our results would suggest that ATP may
also influence specific metabolic path-
ways. In addition to the well-established
role of ATP in cellular metabolism, extra-
cellular ATP appears to be involved in the
regulation of a variety of biologic pro-
cesses, including neurotransmission,
muscle contraction, cardiac function, va-
sodilatation, and liver glycogen metabo-
lism (16). ATP can be released from the
cytoplasm of several cell types and inter-
acts with purinergic P1 and, particularly,
P2 receptors on the surface of many cells
(16). Significantly lower ATP levels have
been found in the liver and in the skeletal
muscle of tumor-bearing rats (34). Rapa-
port and Fontaine (17) showed that intra-
peritoneal ATP administration doubled
hepatic ATP pools and inhibited weight
loss in tumor-bearing mice. These authors
suggested that ATP may inhibit Cori
cycle activity (i.e., conversion of glucose
to lactate in peripheral tissues followed by
gluconeogenesis from lactate followed in
the liver). Studies in isolated hepatocytes
showed that extracellular ATP induced
Ca2+mobilization and influx by stimula-
tion of surface P2 receptors (35) that are
involved in the control of gluconeogen-
esis (36) and glycogenolysis (37). Fur-
thermore, since albumin levels are af-
fected by both nutrition and acute-phase
response, it is possible that the stabiliza-
tion of serum albumin levels by ATP may
be caused by inhibition of the acute-phase
response. In animals, ATP has been
shown to decrease the production of the
proinflammatory cytokines interleukin 1
and interleukin 6 (38). This observation is
noteworthy, since increased serum levels
of these interleukins (39,40) have been
found in patients with advanced cancer
and were suggested to play a prominent
role in progressive weight loss in cancer
(41). In addition to the effects described
above, ATP may have other benefits in
oncology. Preclinical studies showed that
ATP administration may potentiate the
antitumor effects of cytostatics (42) and
radiotherapy (43) and may also have pro-
tective effects against radiation tissue
damage (44).
In conclusion, our results demonstrate
that ATP infusion has marked beneficial
effects on the QOL of patients with ad-
vanced NSCLC. In patients who are los-
ing weight, ATP prevents further weight
loss and maintains muscle strength of
both the upper and the lower extremities.
ATP can be administered as a constant
intravenous infusion without side effects
in the majority of courses; if side effects
occur, they are mild and transient. In con-
trast to earlier pharmacologic attempts to
reverse cancer cachexia, it appears that
ATP might be the first agent with benefi-
cial effects on skeletal muscles of cachec-
Fig. 4. Changes in The Rotterdam Symp-
tom Checklist quality-of-life (QOL)
scores (mean ± 95% confidence interval).
A) Physical score, B) functional score,
and C) overall score. Two-sided P values
for differences between patients in the
adenosine 58-triphosphate (ATP) group
and patients in the control group were
determined with the use of repeated-
measures analysis.
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tic cancer patients. We conclude that ATP
has potential in the palliative management
of lung cancer. Further clinical trials us-
ing an appropriate placebo control are
warranted.
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